Clinical Trial Enrolment for Rare Disease Populations & Clinical Endpoints
Time: 2:15 pm
day: Day Two
Details:
• What level of pre-existing immunity is accepted?
• What level of protein expression is sufficient for different indications?
• What safety biomarkers do you use to understand pathology in man?
